Clinical trial · Observational
Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire
NCT03614689CI-TRIAL-00078929unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To analyze the proportion of hereditary tumors in ovarian cancer patients in China, as well as the spectrum of variations; the ctDNA characteristics in patients with ovarian cancer; the correlation between the clonal status of mutations and therapy response; whether ctDNA detection can be used to predict the risk of ovarian cancer recurrence; and the characteristics of immune repertoire before and after treatment in patients with ovarian cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The ctDNA characteristics in patients with ovarian cancer , the correlation between the clonal status of mutations and therapy response and whether ctDNA detection can be used to predict the risk of ovarian cancer recurrence.
- timeFrame
- 2 years
Secondary outcomes (1)
- measure
- The proportion of hereditary tumors in ovarian cancer patients in China, as well as the spectrum of variations and the characteristics of immune repertoire before and after treatment in patients with ovarian cancer.
- timeFrame
- 1 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who have not received treatment including radiotherapy, chemotherapy, and surgery. * Expected to achieve satisfactory tumor cytoreductive surgery. * Estimated lifetime is more than 3 months. * Understand the research plan and voluntarily participate in the study, sign the informed consent form. * Ability to collect specimens from each time point and provide corresponding clinical information. Exclusion Criteria: * Patients who will receive new adjuvant therapy. * Patients who have other primary cancer. * Pregnant or breast-feeding woman. * Patients with severe mental illness. * Patients achieve unsatisfactory tumor cytoreductive surgery. * Patients who voluntarily withdraw for any reason. * Patients who cannot complete the research plan.
References
Publications (0)
Data not yet available
No reference posted for this study.